EC's Proposal for Simplification of EU MDR/IVDR Regulation in relation to the EU AI Act 2024/1689

The European Commission’s Simplification Digital Package and Omnibus Proposal of 16 December 2025 introduces significant reforms to the regulatory landscape for Artificial Intelligence–enabled Medical Devices (AIeMD). Central to these reforms is the proposed relocation of the MDR/IVDR from Annex I Section A to Section B of Regulation (EU) 2024/1689 (the AI Act)1. This structural change addresses industry concerns related to regulatory burden, innovation barriers, and uncertainty regarding the interaction between the MDR/IVDR and the AI Act. The proposal clarifies that while AI‑enabled medical devices remain high‑risk, the AI Act obligations that apply are limited to the horizontal requirements referenced under Article 2(2), triggering compliance with Articles 8–15. This paper analyses the regulatory intent and technical implications of these amendments, evaluates the supporting guidance in MDCG‑2025‑6, and synthesizes the key issues presented at the Irish MedTech event on 5 March 2026. The findings indicate that the proposal recalibrates regulatory expectations by allowing better integration of AI Act high‑risk obligations within MDR/IVDR conformity assessment pathways, thereby reducing duplication and improving predictability. However, widespread confusion persists among manufacturers, with some reporting abandonment of AI Act implementation altogether. The paper concludes with recommendations for manufacturers, notified bodies, and policymakers as Europe prepares for the AI Act’s entry into force on 2 August 2026.